L-Serine — Safety, Research, Risks & Legal Status

Not medical advice. L-Serine is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	L-Ser; L-2-Amino-3-hydroxypropanoic acid; 2-amino-3-hydroxypropionic acid; CAS 56-45-1
Category	Supplement
CAS Number	56-45-1
Molecular Weight	105.09 g/mol
Regulatory Status (US)	FDA GRAS; dietary supplement; not approved as a drug
Largest Human Trial	Phase I, n=20 ALS patients; Phase IIa (NCT03580616) terminated 2022, unpublished
Endogenous Synthesis Pathway	Serine synthesis pathway from 3-phosphoglycerate (glucose-derived)
Confirmed Genetic Indication	Serine synthesis defects (PSAT1/PSPH mutations, HSAN1) - used as direct metabolite replacement
US legal status	FDA GRAS (Generally Recognized as Safe) designation; approved as a food additive under 21 CFR 172.320. Sold over-the-counter as a dietary supplement in the US without prescription. Not approved as a drug for ALS, Alzheimer's disease, or any other neurodegenerative indication. D-serine (the enantiomer) is not FDA-approved for any therapeutic use. L-serine is not a scheduled or controlled substance.

What is L-Serine?

L-Serine is a naturally occurring, proteinogenic amino acid synthesized endogenously via the serine synthesis pathway from glucose-derived 3-phosphoglycerate. It is considered conditionally essential in the central nervous system, where it serves as a direct precursor to glycine, D-serine, phospholipids (particularly sphingolipids critical for myelin integrity), and folate-cycle one-carbon units. Its presence in virtually all proteins and its roles in neurotransmitter metabolism have generated investigational interest in neuroprotective applications, particularly ALS and Alzheimer's disease, though human trial data remain limited and no pivotal Phase II/III trial has been completed.

How it works

L-Serine's proposed neuroprotective mechanisms include: (1) selective activation of lysosomal autophagic enzymes cathepsins B and L, which enhances proteolysis of misfolded and aggregated proteins - a process impaired across multiple neurodegenerative diseases; (2) serving as the obligate biosynthetic precursor to D-serine, an endogenous co-agonist at the glycine site of NMDA receptors, thereby modulating glutamatergic neurotransmission; (3) acting as a phospholipid precursor for sphingolipid synthesis, supporting myelin maintenance; (4) upregulating PPAR-gamma, an anti-inflammatory transcription factor; and (5) supporting antiapoptotic signaling. Mechanistic work in cell culture and animal models is consistent across studies, though the relative contribution of each pathway in human disease has not been established.

Background & history

L-Serine was first isolated in the early 20th century and has been a well-characterized proteinogenic amino acid for decades. It is produced at commodity scale by major amino acid manufacturers including Ajinomoto (Japan), Evonik Industries (Germany), and Kyowa Hakko Bio (Japan), with no single pharmaceutical firm holding development rights. Clinical interest in neuroprotection emerged partly from observations linking BMAA (a cyanobacterial toxin and L-serine structural analog) to ALS-like pathology in Guamanian populations, and from identification of genetic serine synthesis defects (PSAT1/PSPH mutations) causing heritable sensory neuropathy (HSAN1) and encephalopathy. Academic and institutional investigators - particularly through the Northeast ALS Consortium (NEALS) - have driven the small clinical program.

What the research says

Human clinical evidence is limited and should be interpreted cautiously. A Phase I trial in 20 ALS patients (doses 0.5-15 g twice daily) reported a 34% reduction in ALSFRS-R decline slope (P=0.044) compared to 430 matched historical controls, with approximately 4-fold CSF L-serine elevation in the highest-dose cohort; this was a small, uncontrolled study with historical comparators and results must be regarded as hypothesis-generating only. A Phase IIa randomized controlled trial (NCT03580616) was initiated but terminated by the IRB in December 2022 due to compliance issues; results have not been published as of 2026, leaving the pivotal question of efficacy in ALS unresolved. A separate Phase IIa trial in early Alzheimer's disease (NCT03062449) exists but published outcome data are not available in the research notes. L-serine is also under study in GRIN-related encephalopathy (NCT04646447), a genetic serine deficiency syndrome where it functions as direct replacement therapy. Preclinical evidence is more extensive: vervet monkey ALS models showed reduction in spinal cord pathology markers; mouse Alzheimer's models showed restoration of impaired astrocytic glycolysis, L/D-serine synthesis, and synaptic plasticity. No Phase III trial has been conducted for any indication.

Reported effects

Proposed neuroprotection via enhanced lysosomal autophagy and clearance of misfolded proteins (animal and cell models; limited human data)
NMDA receptor modulation via D-serine precursor activity (mechanistic; clinical significance unclear)
Sphingolipid and myelin precursor support (preclinical)
Anti-inflammatory signaling via PPAR-gamma upregulation (preclinical)
Trend toward slowed ALS functional decline in a single small Phase I trial (n=20; underpowered; historical controls)
Used as direct metabolite replacement in genetic serine synthesis deficiency disorders (HSAN1, PSAT1/PSPH mutations)

Dosing & administration (informational)

The Phase I ALS trial explored doses ranging from 0.5 g to 15 g twice daily (i.e., 1-30 g/day total), with cerebrospinal fluid penetration confirmed at the highest doses. Patients with genetic serine synthesis defects have received approximately 400 mg/kg/day in therapeutic contexts. These are literature-described ranges for informational purposes only and do not constitute a dosing protocol. Optimal dosing for any indication has not been established in adequate controlled trials. Consult a qualified clinician before using L-serine for any medical purpose.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

No serious adverse events reported in Phase I ALS trial or post-market surveillance
Minor GI effects reported: nausea, diarrhea, bloating, appetite loss - transient and dose-dependent
Falls reported in Phase IIa trial population attributed to underlying ALS disease progression, not L-serine
No organ toxicity identified at therapeutic doses including high-dose use (up to 400 mg/kg/day) in pediatric genetic deficiency patients
Theoretical NMDAR excitotoxicity via D-serine dysregulation has not been observed clinically at L-serine doses used in trials
No known drug interactions identified; no scheduled substance status
FDA has received no adverse incident reports for supplemental use per available data

Drug & supplement interactions

N
o
s
p
e
c
i
f
i
c
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
s
h
a
v
e
b
e
e
n
i
d
e
n
t
i
f
i
e
d
i
n
p
u
b
l
i
s
h
e
d
c
l
i
n
i
c
a
l
t
r
i
a
l
d
a
t
a
o
r
p
o
s
t
-
m
a
r
k
e
t
s
a
f
e
t
y
r
e
p
o
r
t
s
.
T
h
e
o
r
e
t
i
c
a
l
c
o
n
s
i
d
e
r
a
t
i
o
n
s
i
n
c
l
u
d
e
p
o
t
e
n
t
i
a
l
m
o
d
u
l
a
t
i
o
n
o
f
N
M
D
A
r
e
c
e
p
t
o
r
a
c
t
i
v
i
t
y
v
i
a
a
l
t
e
r
e
d
D
-
s
e
r
i
n
e
a
v
a
i
l
a
b
i
l
i
t
y
,
w
h
i
c
h
c
o
u
l
d
t
h
e
o
r
e
t
i
c
a
l
l
y
i
n
t
e
r
a
c
t
w
i
t
h
N
M
D
A
r
e
c
e
p
t
o
r
a
n
t
a
g
o
n
i
s
t
s
(
e
.
g
.
,
m
e
m
a
n
t
i
n
e
)
o
r
o
t
h
e
r
g
l
u
t
a
m
a
t
e
r
g
i
c
a
g
e
n
t
s
,
t
h
o
u
g
h
t
h
i
s
h
a
s
n
o
t
b
e
e
n
d
o
c
u
m
e
n
t
e
d
c
l
i
n
i
c
a
l
l
y
.
I
n
d
i
v
i
d
u
a
l
s
o
n
m
e
d
i
c
a
t
i
o
n
s
m
e
t
a
b
o
l
i
z
e
d
v
i
a
f
o
l
a
t
e
o
r
o
n
e
-
c
a
r
b
o
n
p
a
t
h
w
a
y
s
s
h
o
u
l
d
d
i
s
c
u
s
s
u
s
e
w
i
t
h
a
p
r
e
s
c
r
i
b
i
n
g
c
l
i
n
i
c
i
a
n
g
i
v
e
n
L
-
s
e
r
i
n
e
'
s
r
o
l
e
i
n
o
n
e
-
c
a
r
b
o
n
m
e
t
a
b
o
l
i
s
m
.

Who should avoid it

Using L-serine as a replacement for evidence-based ALS treatments (riluzole, edaravone) given absence of pivotal trial data
Expecting therapeutic equivalence to drug-approved therapies based on the single small Phase I trial
Conflating the dietary supplement regulatory status with proof of clinical efficacy
High-dose self-administration without clinical supervision, particularly in individuals with renal impairment or significant GI disease
Confusing L-serine (supplement-grade GRAS) with D-serine (not approved, distinct pharmacology)

How it is commonly combined

No formally studied combination protocols exist in human trials. Preclinical mechanistic work suggests L-serine's autophagy-activating and neurotransmitter-precursor mechanisms are distinct from those of riluzole (glutamate-release inhibition) and edaravone (free radical scavenging), suggesting non-overlapping targets in principle. However, clinical data on combinations are absent, and any co-administration with approved ALS therapies should be disclosed to and supervised by the treating neurologist.

Legal & regulatory. FDA GRAS (Generally Recognized as Safe) designation; approved as a food additive under 21 CFR 172.320. Sold over-the-counter as a dietary supplement in the US without prescription. Not approved as a drug for ALS, Alzheimer's disease, or any other neurodegenerative indication. D-serine (the enantiomer) is not FDA-approved for any therapeutic use. L-serine is not a scheduled or controlled substance.

Quality & harm reduction

L
-
s
e
r
i
n
e
i
s
a
c
o
m
m
o
d
i
t
y
a
m
i
n
o
a
c
i
d
p
r
o
d
u
c
e
d
b
y
m
u
l
t
i
p
l
e
e
s
t
a
b
l
i
s
h
e
d
g
l
o
b
a
l
m
a
n
u
f
a
c
t
u
r
e
r
s
.
P
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
m
a
t
e
r
i
a
l
i
s
p
r
o
d
u
c
e
d
b
y
A
j
i
n
o
m
o
t
o
,
E
v
o
n
i
k
I
n
d
u
s
t
r
i
e
s
(
v
i
a
p
r
o
p
r
i
e
t
a
r
y
e
n
z
y
m
a
t
i
c
s
y
n
t
h
e
s
i
s
)
,
a
n
d
K
y
o
w
a
H
a
k
k
o
B
i
o
.
S
u
p
p
l
e
m
e
n
t
-
g
r
a
d
e
p
r
o
d
u
c
t
s
v
a
r
y
i
n
p
u
r
i
t
y
a
n
d
m
a
n
u
f
a
c
t
u
r
i
n
g
c
o
n
t
r
o
l
s
;
n
o
s
i
n
g
l
e
r
e
g
u
l
a
t
o
r
y
a
u
t
h
o
r
i
t
y
m
a
n
d
a
t
e
s
p
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
p
u
r
i
t
y
f
o
r
O
T
C
s
u
p
p
l
e
m
e
n
t
s
a
l
e
s
.
C
o
n
s
u
m
e
r
s
s
e
e
k
i
n
g
r
e
s
e
a
r
c
h
-
g
r
a
d
e
m
a
t
e
r
i
a
l
s
h
o
u
l
d
l
o
o
k
f
o
r
c
e
r
t
i
f
i
c
a
t
e
s
o
f
a
n
a
l
y
s
i
s
f
r
o
m
a
c
c
r
e
d
i
t
e
d
t
h
i
r
d
-
p
a
r
t
y
l
a
b
s
a
n
d
m
a
n
u
f
a
c
t
u
r
i
n
g
u
n
d
e
r
c
G
M
P
c
o
n
d
i
t
i
o
n
s
.
N
o
s
i
n
g
l
e
c
o
m
p
a
n
y
c
o
n
t
r
o
l
s
t
h
e
m
a
r
k
e
t
o
r
a
p
r
o
p
r
i
e
t
a
r
y
f
o
r
m
u
l
a
t
i
o
n
.

Safer, legal alternative we recommend

Brainy Bunch Formula. For the same cognitive-support goal, our Brain & Focus Formula is a legal nootropic blend you can buy today.

See our recommended pick

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is L-serine an approved treatment for ALS?

No. L-serine is not FDA-approved for ALS or any other neurodegenerative disease. It is sold as a dietary supplement under GRAS status. The only completed human ALS trial was a Phase I study in 20 patients with a positive but underpowered trend; the Phase IIa trial was terminated before completion and results were not published.

What is the recommended dose of L-serine?

There is no established therapeutic dose for any indication in humans. The Phase I ALS trial used 0.5-15 g twice daily; these are literature-described ranges, not a protocol. Consult a clinician before using L-serine for any medical purpose.

Is L-serine the same as D-serine?

No. L-serine and D-serine are enantiomers with distinct pharmacology. L-serine is the naturally occurring form found in food and the body and holds FDA GRAS status. D-serine is an endogenous NMDA receptor co-agonist synthesized from L-serine; it is not FDA-approved and has a different risk profile.

Why was the Phase IIa ALS trial terminated?

ClinicalTrials.gov (NCT03580616) records the trial as terminated in December 2022 due to IRB compliance issues. The decision was administrative rather than a safety signal. Results have not been published as of 2026, so the efficacy question in ALS remains open.

Is L-serine safe to take as a supplement?

The available safety data - from a Phase I trial, genetic deficiency treatment at high doses, and FDA post-market surveillance - show no serious adverse events and only minor, transient GI side effects (nausea, bloating, diarrhea). However, long-term safety data from controlled trials are absent. Individuals with complex medical conditions or on medications should consult a clinician.

Does L-serine have evidence for Alzheimer's disease?

Animal model data (mouse) show L-serine restored impaired astrocytic glycolysis, L/D-serine synthesis, and synaptic plasticity. A Phase IIa trial in early Alzheimer's disease (NCT03062449) exists, but published outcome data are not available in the current literature as of 2026. Evidence in human Alzheimer's disease is currently preclinical or unpublished.

References & further reading

PubMed: L-Serine cathepsin B cathepsin L lysosomal autophagy neuroprotection mechanism 2020 Neurotoxicity Research
PubMed: Phase I clinical trial L-serine ALS safety tolerability ALSFRS-R 2016 Amyotrophic Lateral Sclerosis Frontotemporal Degeneration
PubMed: L-Serine neurological implications therapeutic potential review Biomedicines 2023 PMC10452085
ClinicalTrials.gov: NCT03580616 L-serine ALS tolerability efficacy Phase IIa terminated 2022
ClinicalTrials.gov: NCT03062449 L-serine early Alzheimer disease Phase IIa